Additive effects of combined blockade of AT1receptor and HMG-CoA reductase on left ventricular remodeling in infarcted rats
Authors:
- Mei-Shu LinMLMei-Shu Lin
- Tsai-Fwu ChouTCTsai-Fwu Chou
- Nen-Chung ChangNCNen-Chung Chang
- 1 September 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 291 (3) , H1281-H1289
Abstract
Both angiotensin receptor antagonists and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been shown to attenuate cardiomyocyte hypertrophy after myocardial infarction. Whether combination treatment may be superior to either drug alone on cardiomyocyte hypertrophy remains unclear. After ligation of the left anterior descending artery, rats were randomized to both, one, or neither of the angiotensin receptor antagonists olmesartan (0.01, 0.1, 1, and 2 mg·kg−1·day−1) and HMG-CoA reductase inhibitor pravastatin (5 mg·kg−1·day−1) for 4 wk. Each drug, when given alone, decreased cardiomyocyte sizes isolated by enzymatic dissociation at the border zone when compared with vehicles. However, compared with either drug alone, combined olmesartan and pravastatin prevent cardiomyocyte hypertrophy to a larger extent, which was further confirmed by downregulation of the left ventricular atrial natriuretic peptide mRNA. The myocardial endothelin-1 levels at the border zone were 6.5-fold higher ( P <0.0001) in the vehicle group compared with the sham group, which can be inhibited after pravastatin administration. Combination treatment significantly attenuated cardiomyocyte hypertrophy in a dose-dependent manner, although tissue endothelin-1 levels remained stable in combination groups of different olmesartan doses. Measurements of the arrhythmic score mirrored those of cardiomyocyte hypertrophy. Dual therapy with pravastatin and olmesartan, which produced an additive reduction in cardiomyocyte hypertrophy and cardiac fibrosis after myocardial infarction through different mechanisms, decreases the propensity of the heart to arrhythmogenesis. Pravastatin administration provided favorable ventricular remodeling, probably through decreased tissue endothelin-1 level. In contrast, olmesartan-related attenuated cardiomyocyte hypertrophy is independent of endothelin-1 pathway.Keywords
This publication has 37 references indexed in Scilit:
- Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1Biochemical and Biophysical Research Communications, 2004
- Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive ratCardiovascular Pathology, 2004
- Peroxisome Proliferator-Activated Receptor Activators Inhibit Thrombin-Induced Endothelin-1 Production in Human Vascular Endothelial Cells by Inhibiting the Activator Protein-1 Signaling PathwayCirculation Research, 1999
- Ionic basis of ventricular arrhythmias in remodeled rat heart during long-term myocardial infarctionCardiovascular Research, 1999
- Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failureJournal of Molecular and Cellular Cardiology, 1995
- Markedly different effects on ventricular remodelling result in a decrease in inducibility of ventricular arrhythmiasJACC, 1994
- Electrophysiological Responses of Hypertrophied Rat Myocardium to Combined Hypoxia, Hyperkalemia, and AcidosisJournal of Cardiovascular Pharmacology, 1991
- Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cellsBiochemical and Biophysical Research Communications, 1989
- Significance of ventricular arrhythmias initiated by programmed ventricular stimulation: the importance of the type of ventricular arrhythmia induced and the number of premature stimuli required.Circulation, 1984
- The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme—A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicksAtherosclerosis, 1980